Following the FDA approval, the radiological diagnostic drug 68Ga-NY104(NYM005), which was fully self-developed by Norroy, was approved clinical trial by CDE December 2023, which marks the first product pipeline of Norroy to achieve clinical approval in China and the United States within a few months.
The theranostics of renal clear cell carcinoma (ccRCC) is one of the major unmet clinical needs. The next work of Norroy will quickly carry out the clinical trial work of 68Ga-NY104, and strive to promote the early listing of the nuclear drug for the benefit of patients around the world.
Norroy will continue to innovate to create new possibilities for precision medicine and bring more good news. In order to further expand and deepen the global layout of the company's products, Norroy plans to submit IND applications every year in the future, quickly promote the pipelines into the late clinical stage, promote the original innovation nuclear drug results transformation, in order to bring more breakthrough options.